Predictive value of ERCC1 and RRM1 gene single-nucleotide polymorphisms for first-line platinum- and gemcitabine-based chemotherapy in non-small cell lung cancer patients

Oncology Reports

Volumn 30, Issue 5, 2013, Pages 2385-2398

  Mlak, Radosław ^a,b   Krawczyk, Paweł ^a   Ramlau, Rodryg ^b,c   Kalinka Warzocha, Ewa ^d   Wasylecka Morawiec, Maja ^d   Wojas Krawczyk, Kamila ^a   Kucharczyk, Tomasz ^a,e   Homa, Iwona ^a   Kozioł, Piotr ^a   Ciesielka, Marzanna ^a   Chudziak, Dorota ^a   Milanowski, Janusz ^a,f  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b Janusz Zeyland   (Poland)

^c POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^d Regional Hospital in Lodz   (Poland)

^e MEDICAL UNIVERSITY OF WARSAW   (Poland)

^f INSTITUTE OF AGRICULTURAL MEDICINE   (Poland)

Author keywords

Excision repair cross complementing group 1; Gemcitabine; Non small cell lung cancer; Platinum; Ribonucleotide reductase M1

Indexed keywords

CARBOPLATIN; CISPLATIN; DNA; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GEMCITABINE; RIBONUCLEOTIDE REDUCTASE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; DNA ISOLATION; DRUG EFFICACY; ERCC1 GENE; FEMALE; GENE MUTATION; GENOTYPE; HETEROZYGOTE; HUMAN; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; LUNG SURGERY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PHARMACOGENETICS; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REAL TIME POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RRM1 GENE; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL TIME; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; DEOXYCYTIDINE; DNA-BINDING PROTEINS; ENDONUCLEASES; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PLATINUM; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; TUMOR SUPPRESSOR PROTEINS;

EID: 84885047885     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2696     Document Type: Article

References (31)

1. Dela Cruz CS, Tanoue LT and Matthay RA: Lung cancer: epidemiology, etiology, and prevention. Clin Chest Med 32: 605-644, 2011.
2. NSCLC Meta-Analysis Collaborative Group: Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer. A systemic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol 26: 4617-4625, 2008.
3. Simon GR, Ismail-Khan R and Bepler G: Nuclear excision repair-based personalized therapy for non-small cell lung cancer: from hypothesis to reality. Int J Biochem Cell Biol 39: 1318-1328, 2007.
4. Jordheim LP, Sève P, Trédan O, et al: The ribonucleotide reductase large subunit (RRM1) as a predictive factor in patients with cancer. Lancet Oncol 12: 693-702, 2011.
5. Stewart DJ: Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer. Crit Rev Oncol Hematol 75: 173-234, 2010.
6. Bepler G, Sharma S, Gautam A, et al: Tumor genotype, RRM1 expression and outcome of patients with lung cancer. Eur J Cancer 38 (Suppl 7): 82 (Abstr 265), 2003.
7. Vilmar A and Sorensen JB: Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature. Lung Cancer 64: 131-139, 2009.
8. Olaussen K, Dunant A, Fouret P, et al: DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 335: 981-983, 2006.
9. Ceppi P, Volante M, Novello S, et al: ERCC1 and RRM1 gene expression but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Ann Oncol 17: 1818-1825, 2006.
10. Paz-Ares L, Souliers D, Melezinek I, et al: Clinical outcome in non-small cell lung cancer patients with EGFR mutation: pooled analysis. J Cell Mol Med 14: 51-69, 2010.
11. Mitsudomi T, Morita S, Yatabe Y, et al: Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomized phase 3 trial. Lancet Oncol 11: 121-128, 2010.
12. Zheng Z, Chen T, Li X, et al: DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med 356: 800-808, 2007.
13. Bepler G, Olaussen KA, Vataire AL, et al: ERCC1 and RRM1 in the international adjuvant lung trial by automated quantitative in situ analysis. Am J Pathol 178: 69-78, 2011.
14. Cobo M, Isla D, Massuti B, et al: Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J Clin Oncol 25: 2747-2754, 2007.
15. Simon GR, Schell MJ, Begum M, et al: Preliminary indication of survival benefit from ERCC1 and RRM1-tailored chemotherapy in patients with advanced non-small cell lung cancer: evidence from an individual patient analysis. Cancer 118: 2525-2531, 2012.
16. McWhinney SR and McLeod HL: Using germline genotype in cancer pharmacogenetic studies. Pharmacogenomics 10: 489-493, 2009.
17. Bepler G, Zheng Z, Gautam A, et al: Ribonucleotide reductase M1 gene promoter activity, polymorphisms, population frequencies, and clinical relevance. Lung Cancer 47: 183-192, 2005.
18. Chang PM, Tzeng CH, Chen PM, et al: ERCC1 codon 118 C→T polymorphism associated with ERCC1 expression and outcome of FOLFOX-4 treatment in Asian patients with metastatic colorectal carcinoma. Cancer Sci 100: 278-283, 2009.
19. Isla D, Sarries C, Rosell R, et al: Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. Ann Oncol 15: 1194-1203, 2004.
20. Tibaldi C, Giovannetti E, Vasile E, et al: Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res 14: 1797-1803, 2008.
21. Ryu JS, Hong YC, Han HS, et al: Associated between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy. Lung Cancer 44: 311-316, 2004.
22. Su D, Ma S, Liu P, et al: Genetic polymorphisms and treatment response in advanced non-small cell lung cancer. Lung Cancer 56: 281-288, 2007.
23. Krawczyk P, Wojas-Krawczyk K, Mlak R, et al: Predictive value of ERCC1 single-nucleotide polymorphism in patients receiving platinum-based chemotherapy for locally-advanced and advanced non-small cell lung cancer: a pilot study. Folia Histochem Cytobiol 50: 80-86, 2012.
24. Ren S, Zhou S, Wu F, et al: Association between polymorphisms of DNA repair genes and survival of advanced NSCLC patients treated with platinum-based chemotherapy. Lung Cancer 75: 102-109, 2012.
25. Kalikaki A, Kanaki M, Vassalou H, et al: DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer. Clin Lung Cancer 10: 118-123, 2009.
26. Yu D, Shi J, Sun T, et al: Pharmacogenetic role of ERCC1 genetic variants in treatment response of platinum-based chemotherapy among advanced non-small cell lung cancer patients. Tumour Bio 33: 877-884, 2012.
27. Takenaka T, Yano T, Kiyohara C, et al: Effects of excision repair cross-complementation group 1 (ERCC1) single nucleotide polymorphisms on the prognosis of non-small cell lung cancer patients. Lung Cancer 67: 101-107, 2010.
28. Ludovini V, Floriani I, Pistola L, et al: Association of cytidine deaminase and xeroderma pigmentosum group D polymorphisms with response, toxicity, and survival in cisplatin/gemcitabine-treated advanced non-small cell lung cancer patients. J Thorac Oncol 6: 2018-2026, 2011.
29. Liao WY, Shih JY, Chang GC, et al: Genetic polymorphism of XRCC1 Arg399Gln is associated with survival in non-small-cell lung cancer patients treated with gemcitabine/platinum. J Thorac Oncol 7: 973-981, 2012.
30. Feng JF, Wu JZ, Hu SN, et al: Polymorphisms of the ribonucleotide reductase M1 gene and sensitivity to platin-based chemotherapy in non-small cell lung cancer. Lung Cancer 66: 344-349, 2009.
31. Song D, Ai-Lin G, Zhi-Hong Ch, et al: RRM1 single nucleotide polymorphism -37C>A correlates with progression-free survival in NSCLC patients after gemcitabine-based chemotherapy. J Hematol Oncol 3: 10, 2010.